Pamela Lukasewicz Ferreira

Plasma versus neuroimaging biomarkers for Alzheimer’s disease clinical trials

Research priorities to achieve widespread use of blood-based biomarkers in Alzheimer’s disease

Value of p-tau231 in early Alzheimer’s disease

Alzheimer’s disease plasma biomarkers across the spectrum: which perform best?

Strengthening diversity in dementia biomarkers research

The use of Alzheimer’s disease plasma biomarkers in the clinic: further research needed

Upcoming plasma biomarkers for Alzheimer’s disease: Aβ, p-tau and GFAP

Comparing the performance of novel biomarkers across the spectrum of Alzheimer’s disease

Plasma p-Tau181 and p-Tau231 offer complementary information in Alzheimer’s

APP/PS1 mutations associated with earlier cognitive decline in offspring rodents